Nevertheless, SGLT2 inhibitors are now the standard of care for HFpEF, based on evidence from the EMPEROR-Preserved [27] and DELIVER [28] trials, which showed up to a 20% reduction in HF hospitalizations and cardiovascular death, regardless of obesity status. Here, SLC5A2 is linked to obesity disorder.